CURE.DE vs. NUKL.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and NUKL.DE (VanEck Uranium and Nuclear Technologies UCITS ETF A) are both exchange-traded funds - CURE.DE is a Health & Biotech Equities fund tracking the MVIS Global Future Healthcare ESG, while NUKL.DE is a Energy Equities fund tracking the MarketVector Global Uranium and Nuclear Energy Infrastructure. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 41.91%/yr for NUKL.DE. At a 0.35 correlation, their price movements are largely independent. CURE.DE charges 0.35%/yr vs 0.55%/yr for NUKL.DE.
Performance
CURE.DE vs. NUKL.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than NUKL.DE's 11.67% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 6.73%
- YTD
- -5.10%
- 6M
- -8.62%
- 1Y
- 6.04%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
NUKL.DE
- 1D
- 0.87%
- 1M
- -5.22%
- YTD
- 11.67%
- 6M
- 4.25%
- 1Y
- 49.71%
- 3Y*
- 41.91%
- 5Y*
- —
- 10Y*
- —
CURE.DE vs. NUKL.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -9.31% |
NUKL.DE VanEck Uranium and Nuclear Technologies UCITS ETF A | 11.67% | 51.50% | 38.03% | 24.46% |
Correlation
The correlation between CURE.DE and NUKL.DE is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Feb 9, 2023 | 0.35 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. NUKL.DE — Risk / Return Rank
CURE.DE
NUKL.DE
CURE.DE vs. NUKL.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and VanEck Uranium and Nuclear Technologies UCITS ETF A (NUKL.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | NUKL.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.92 | ||
| Sortino ratioReturn per unit of downside risk | -1.25 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.21 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 1.86 | -1.56 |
| Martin ratioReturn relative to average drawdown | 0.68 | 4.43 | -3.76 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | NUKL.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 1.21 | -0.92 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 1.10 | -1.24 |
Drawdowns
CURE.DE vs. NUKL.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, smaller than the maximum NUKL.DE drawdown of -37.52%. Use the drawdown chart below to compare losses from any high point for CURE.DE and NUKL.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | NUKL.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -37.52% | +2.72% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -27.12% | +8.05% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -37.52% | +8.20% |
Current DrawdownCurrent decline from peak | -15.66% | -12.83% | -2.83% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -7.79% | -7.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 11.43% | -2.90% |
Volatility
CURE.DE vs. NUKL.DE - Volatility Comparison
The current volatility for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) is 5.73%, while VanEck Uranium and Nuclear Technologies UCITS ETF A (NUKL.DE) has a volatility of 11.05%. This indicates that CURE.DE experiences smaller price fluctuations and is considered to be less risky than NUKL.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | NUKL.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 11.05% | -5.32% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 28.97% | -13.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 41.82% | -21.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 34.24% | -13.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 34.24% | -13.50% |
CURE.DE vs. NUKL.DE - Expense Ratio Comparison
CURE.DE has a 0.35% expense ratio, which is lower than NUKL.DE's 0.55% expense ratio.
Dividends
CURE.DE vs. NUKL.DE - Dividend Comparison
Neither CURE.DE nor NUKL.DE has paid dividends to shareholders.
Frequently Asked Questions
CURE.DE and NUKL.DE have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, CURE.DE is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE is cheaper with a 0.35% expense ratio, compared with 0.55% for NUKL.DE.
CURE.DE is categorized as Health & Biotech Equities, while NUKL.DE is Energy Equities. CURE.DE tracks MVIS Global Future Healthcare ESG, while NUKL.DE tracks MarketVector Global Uranium and Nuclear Energy Infrastructure. Their fees differ too: 0.35% for CURE.DE and 0.55% for NUKL.DE.
Find the right allocation for CURE.DE and NUKL.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer